nach oben

Clinical Pharmacokinetics

Erschienen in:

01.05.2000 | Review Article

Dosage Adjustments for Antibacterials in Obese Patients

Applying Clinical Pharmacokinetics

verfasst von: David T. Bearden, Dr Keith A. Rodvold

Erschienen in: Clinical Pharmacokinetics | Ausgabe 5/2000

Einloggen, um Zugang zu erhalten

Abstract

Obesity is associated with physiological changes that can alter the pharmacokinetic parameters of many drugs. Vancomycin and the aminoglycosides are the only antibacterials that have been extensively investigated in the obese population. The apparent volume of distribution (Vd) and total body clearance of vancomycin are increased in obese patients and have a better correlation with total bodyweight (TBW) than with ideal bodyweight (IBW). The Vd of aminoglycosides is increased in obesity and can be estimated from an adjusted body-weight that accounts for a fraction of the excess bodyweight (TBW — IBW). These observed changes in pharmacokinetic parameters of vancomycin and aminoglycosides in obese patients may necessitate a deviation from the commonly recommended dosages administered to non-obese individuals.

There are limited data regarding the pharmacokinetics of other antibacterial classes in obese patients. The available information for Cephalosporins suggests that dosages may need to be increased in obese patients in order to obtain similar serum and tissue concentrations as in non-obese patients. Additional pharmacokinetic studies of other antibacterial classes are required in this special patient population.

Blouin RA, Warren GW. Pharmacokinetic considerations in obesity. J Pharm Sci. 1999; 88: 1–7.PubMedCrossRef

Kotlyar M, Carson SW. Effects of obesity on the cytochrome P450 enzyme system. Int J Clin Pharmacol Ther. 1999; 37: 8–19.PubMed

Wurtz R, Itokazu G, Rodvold K. Antimicrobial dosing in obese patients. Clin Infect Dis. 1997; 25: 112–8.PubMedCrossRef

Devine BJ. Gentamicin therapy. Drug Intell Clin Pharm. 1974; 8: 650–5.

Clinical guidelines on the identification, Evaluation, and treatment of overweight and obesity in adults — the evidence report. National Institutes of Health. Obes Res 1998; 6 Suppl.: 51S–209S.

Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antimicrobial dosing of mice and men. Clin Infect Dis. 1998; 26: 1–12.PubMedCrossRef

Forrest A, Nix DE, Ballow CH, et al. Pharmacodynamics of intravenous Ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother. 1993; 37: 1073–81.PubMedCrossRef

Preston SL, Drusano GL, Berman AL, et al. Pharmacokinetics of levofloxacin: a new paradigm for early clinical trials. JAMA. 1998; 279: 125–9.PubMedCrossRef

Wada DR, Drover DR, Lemmens HJ. Determination of the distribution volume that can be used to calculate the intravenous loading dose. Clin Pharmacokinet. 1998; 35: 1–7.PubMedCrossRef

10.

Ritschel WA, Kaul S. Prediction of apparent volume of distribution in obesity. Methods Find Exp Clin Pharmacol. 1986; 8: 239–47.PubMed

11.

Holford NH. A size standard for pharmacokinetics. Clin Pharmacokinet. 1996; 30: 329–32.PubMedCrossRef

12.

Morgan DJ, Bray KM. Lean body mass as a predictor of drug dosage. Implications for drug therapy. Clin Pharmacokinet. 1994; 26: 292–307.

13.

Hallynck TH, Soep HH, Thomis JA, et al. Should clearance be normalised to body surface or to lean body mass. Br J Clin Pharmacol. 1981; 11: 523–6.PubMedCrossRef

14.

Anderson PO, Lane JR. Lean body mass and volume of distribution [letter]. Am J Hosp Pharm. 1984; 4: 658.

15.

Cockcroft DW, Gault MH. Prediction of Creatinine clearance from serum Creatinine. Nephron. 1976; 16: 31–41.PubMedCrossRef

16.

Jelliffe RW. Estimation of Creatinine clearance when urine cannot be collected. Lancet 1971; I: 975–6.CrossRef

17.

Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum Creatinine: a new prediction equation. Ann Intern Med. 1999; 130: 461–70.PubMed

18.

Dionne RE, Bauer LA, Gibson GA, et al. Estimating Creatinine clearance in morbidity obese patients. Am J Hosp Pharm. 1981; 38: 841–4.PubMed

19.

Snider RD, Kruse JA, Bander JJ, et al. Accuracy of estimated Creatinine clearance in obese patients with stable renal function in the intensive care unit. Pharmacotherapy. 1995; 15: 747–53.PubMed

20.

Winter ME. BasicClinical Pharmacokinetics. 3rd ed. Vancouver (WA): Applied Therapeutics, Inc., 1994.

21.

Sawyer WT, Canaday BR, Poe TE, et al. Variables affecting Creatinine clearance prediction. Am J Hosp Pharm. 1983; 40: 2175–80.PubMed

22.

Bauer LA, Edwards WA, Dellinger EP, et al. Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients. Eur J Clin Pharmacol. 1983; 24: 643–7.PubMedCrossRef

23.

Leader WG, Tsubaki T, Chandler MH. Creatinine-clearance estimates for predicting gentamicin pharmacokinetic values in obese patients. Am J Hosp Pharm. 1994; 51: 2125–30.PubMed

24.

Salazar DE, Corcoran GB. Predicting Creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass. Am J Med. 1988; 84: 1053–60.PubMedCrossRef

25.

Spinler SA, Nawarskas JJ, Boyce EG, et al. Predictive performance of ten equations for estimating Creatinine clearance in cardiac patients. Iohexol Cooperative Study Group. Ann Pharmacother. 1998; 32: 1275–83.

26.

Lake KD, Peterson CD. A simplified dosing method for initiating vancomycin therapy. Pharmacotherapy. 1985; 5: 340–4.PubMed

27.

DuBois D, DuBois ER. Measurement of the surface area of man. Arch Intern Med. 1915; 15: 868–81.CrossRef

28.

Penzak SR, Gubbins PO, Rodvold KA, et al. Therapeutic drug monitoring of vancomycin in a morbidly obese patient. Ther Drug Monit. 1998; 20: 261–5.PubMedCrossRef

29.

Rodvold KA, Zokufa H, Rotschafer JC. Routine monitoring of serum vancomycin concentrations: can waiting be justified. Clin Pharm. 1987; 6: 655–8.PubMed

30.

Moellering RC. Monitoring serum vancomycin levels: climbing the mountain because it is there. Clin Infect Dis. 1994; 18: 544–6.PubMedCrossRef

31.

Cantu TG, Yamanaka-Yuen NA, Lietman PS. Serum vancomycin concentrations: reappraisal of their clinical value. Clin Infect Dis. 1994; 18: 533–43.PubMedCrossRef

32.

Rodvold KA, Everett JA, Pryka RD, et al. Pharmacokinetics and administration regimens of vancomycin in neonates, infants and children. Clin Pharmacokinet. 1997; 33: 32–51.PubMedCrossRef

33.

Moellering RC, Krogstad DJ, Greenblatt DJ. Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Ann Intern Med. 1981; 94: 343–6.PubMed

34.

Matzke GR, McGory RW, Halstenson CE, et al. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother. 1984; 25: 433–7.PubMedCrossRef

35.

Rodvold KA, Blum RA, Fischer JH, et al. Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother. 1988; 32: 848–52.PubMedCrossRef

36.

Vance-Bryan K, Guay DR, Gilliland SS, et al. Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique. Antimicrob Agents Chemother. 1993; 37: 436–40.PubMedCrossRef

37.

Ducharme MP, Slaughter RL, Edwards DJ. Vancomycin pharmacokinetics in a patient population: effect of age, gender, and body weight. Ther Drug Monit. 1994; 16: 513–8.PubMedCrossRef

38.

Bauer LA, Black DJ, Lill JS. Vancomycin dosing in morbidly obese patients. Eur J Clin Pharmacol. 1998; 54: 621–5.PubMedCrossRef

39.

Blouin RA, Bauer LA, Miller DD, et al. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother. 1982; 21: 575–80.PubMedCrossRef

40.

Moore RD, Smith CR, Lietman PS. Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. Am J Med. 1984; 77: 657–62.PubMedCrossRef

41.

Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis. 1987; 155: 93–9.PubMedCrossRef

42.

Deziel-Evans LM, Murphy JE, Job ML. Correlation of pharmacokinetic indices with therapeutic outcome in patients receiving aminoglycosides. Clin Pharm. 1986; 5: 319–24.PubMed

43.

Rodvold KA, Danziger LH, Quinn JP. Single daily doses of aminoglycosides [letter]. Lancet. 1997; 350: 1412.PubMedCrossRef

44.

Kashuba AD, Bertino Jr JS, Nafziger AN. Dosing of aminoglycosides to rapidly attain pharmacodynamic goals and hasten therapeutic response by using individualized pharmacokinetic monitoring of patients with pneumonia caused by gram-negative organisms. Antimicrob Agents Chemother. 1998; 42: 1842–4.PubMed

45.

Kashuba AD, Nafziger AN, Drusano GL, et al. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother 1989; 43: 623–9.

46.

Corcoran GB, Salazar DE. Obesity as a risk factor in drug-induced organ injury. IV. Increased gentamicin nephrotoxicity in the obese overfed rat. J Pharmacol Exp Ther. 1989; 248: 17–22.

47.

Corcoran GB, Salazar DE, Shentag JJ. Excessive aminoglycoside nephrotoxicity in obese patients [letter]. Am J Med. 1988; 85: 279.PubMedCrossRef

48.

Salazar DE, Shentag JJ, Corcoran GB. Obesity as a risk factor in drug-induced organ injury. V Toxicokinetics of gentamicin in the obese overfed rat. Drug Metab Dispos. 1992; 20: 402–6.

49.

Schwartz SN, Pazin GJ, Lyon JA, et al. A controlled investigation of the pharmacokinetics of gentamicin and tobramycin in obese subjects. J Infect Dis. 1978; 138: 499–505.PubMedCrossRef

50.

Blouin RA, Mann HJ, Griffen WO, et al. Tobramycin pharmacokinetics in morbidly obese patients. Clin Pharmacol Ther. 1979; 26: 508–12.PubMed

51.

Bauer LA, Blouin RA, Griffen WO, et al. Amikacin pharmaco-kinetics in morbidly obese patients. Am J Hosp Pharm. 1980; 37: 519–22.PubMed

52.

Korsager S. Administration of gentamicin to obese patients. Int J Clin Pharmacol TherToxicol. 1980; 18: 549–53.

53.

Sketris I, Lesar T, Zaske DE, et al. Effect of obesity on gentamicin pharmacokinetics. J Clin Pharmacol. 1981; 2: 288–93.

54.

Traynor AM, Nafziger AN, Bertino JS. Aminoglycoside dosing weight correction factors for patients of various body sizes. Antimicrob Agents Chemother. 1995; 39: 545–8.PubMedCrossRef

55.

Blouin RA, Brouwer KL, Record KE, et al. Amikacin pharmacokinetics in morbidly obese patients undergoing gastric-bypass surgery. Clin Pharm. 1985; 4: 70–2.PubMed

56.

Chiba K, Tsuchiya M, Kato J, et al. Cefotiam disposition in markedly obese athlete patients, Japanese sumo wrestlers. Antimicrob Agents Chemother. 1989; 33: 1188–92.PubMedCrossRef

57.

Yost RL, Derendorf H. Disposition of cefotaxime and its des-acetyl metabolite in morbidly obese male and female subjects. Ther Drug Monit. 1986; 8: 189–94.PubMedCrossRef

58.

Kampmann JP, Klein H, Lumholtz B, et al. Ampicillin and Propylthiouracil pharmacokinetics in intestinal bypasss patients followed up to a year after operation. Clin Pharmacokinet. 1984; 9: 168–76.PubMedCrossRef

59.

Allard S, Kinzig M, Bovin G, et al. Intravenous Ciprofloxacin disposition in obesity. Clin Pharmacol Ther. 1993; 54: 368–73.PubMedCrossRef

60.

Caldwell JB, Nilsen AK. Intravenous Ciprofloxacin dosing in a morbidly obese patient [letter]. Ann Pharmacother. 1994; 28: 806.PubMed

61.

Garrett ER, Suverkrup RS, Eberst K, et al. Surgically affected sulfisoxazole pharmacokinetics in the morbidly obese. Biopharm Drug Dispos 1980; 2: 329–65.CrossRef

62.

Yuk J, Nightingale CH, Sweeney K, et al. Pharmacokinetics of nafcillin in obesity. J Infect Dis. 1988; 157: 1088–9.PubMedCrossRef

63.

Cohen LG, DiBiasio A, Lisco SJ, et al. Fluconazole serum concentrations and pharmacokinetics in an obese patient. Pharmacother. 1997; 17: 1023–6.

64.

Gillum JG, Johnson M, Lavoie S, et al. Flucytosine dosing in an obese patient with extrameningeal cryptococcal infection. Pharmacother. 1995; 15: 251–3.

65.

Geiseler PJ, Manis RD, Maddux MS. Dosage of antituberculosis drugs in obese patients. Am Rev Respir Dis. 1985; 131: 944–6.PubMed

66.

Forse RA, Karam B, MacLean LD, et al. Antibiotic prophylaxis for surgery in morbidly obese patients. Surgery. 1989; 106: 750–7.PubMed

67.

Mann HJ, Buchwald H. Cefamandole distribution in serum, adipose tissue, and wound drainage in morbidly obese patients. Drug Intell Clin Pharm. 1986; 20: 869–73.PubMed

68.

Pories WJ, van Rij AM, Burlingham BT, et al. Prophylactic cefazolin in gastric bypass surgery. Surgery. 1981; 90: 426–32.PubMed

69.

Mehta U, Malone M, Alger S. Cefazolin use in clinically severe obese patients undergoing gastric restrictive surgery. Ann Pharmacother. 1995; 29: 935–6.PubMed

Titel: Dosage Adjustments for Antibacterials in Obese Patients
Applying Clinical Pharmacokinetics
verfasst von: David T. Bearden
Dr Keith A. Rodvold
Publikationsdatum: 01.05.2000
Verlag: Springer International Publishing
Erschienen in: Clinical Pharmacokinetics / Ausgabe 5/2000
Print ISSN: 0312-5963
Elektronische ISSN: 1179-1926
DOI: https://doi.org/10.2165/00003088-200038050-00003

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Dosage Adjustments for Antibacterials in Obese Patients

Applying Clinical Pharmacokinetics

Abstract

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2000

Choosing the Right Nonsteroidal Anti-Inflammatory Drug for the Right Patient

Biotransformation of Post-Clozapine Antipsychotics

Methods for Clinical Monitoring of Cyclosporin in Transplant Patients

Impact of Population Pharmacokinetic-Pharmacodynamic Analyses on the Drug Development Process